Last reviewed · How we verify
NCT05373615
Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy
Phase 1 trial testing Cefiderocol in Pharmacokinetics in 14 participants. Completed in 20 November 2024.
20 November 2024
Quick facts
| Lead sponsor | Hartford Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 14 |
| Start date | 25 July 2022 |
| Primary completion | 20 November 2024 |
| Estimated completion | 20 November 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cefiderocol (CEFIDEROCOL) — full drug profile →
Conditions studied
- Pharmacokinetics — all drugs for Pharmacokinetics →
Sponsor
Hartford Hospital
Who can join
Adults 18 to 120, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Continuous renal replacement therapies (CRRT) such as continuous venovenous hemofiltration are used to provide renal support for critically ill patients with acute kidney injury (AKI), particularly patients who are hemodynamically unstable. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how CRRT affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, Cefiderocol, in critically ill patient receiving CRRT.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05373615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cefiderocol
Trials testing the same drug.
- NCT07465432 — Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries · Phase 4 · recruiting
- NCT07004049 — Optimising TREATment for Severe Gram-Negative Bacterial Infections · Phase 4 · recruiting
- NCT06547554 — A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants · Phase 1 · completed
- NCT06086626 — A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants · Phase 2 · completed
- NCT05789199 — Use of Cefiderocol in the Management of Gram-Negative Infections · completed
Other recruiting trials for Pharmacokinetics
Currently open trials in the same condition.
- NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
- NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
- NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
- NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
- NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting
Other Hartford Hospital trials
Trials by the same sponsor.
- NCT04855526 — THC + CBD and Memory Study · EARLY_PHASE1 · not yet recruiting
- NCT06484621 — Motivating Increases in Physical Activity for Prevention of Weight Regain After Metabolic Bariatric Surgery · NA · recruiting
- NCT06481436 — Use of Artificial Intelligence by Urogynecologic Patients · NA · active not recruiting
- NCT06329518 — Rezafungin Pharmacokinetics in Patients on ECMO · Phase 1 · withdrawn
- NCT06123702 — Cannabidiol Effects on Fear Extinction in Social Phobia · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05373615 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hartford Hospital
- Last refreshed: 18 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing